Disclosure of Interest  None Declared.

PWE-144  FRAX SCORE IN THE ASSESSMENT OF BONE MINERAL DENSITY CHANGES IN TENOFOVIR TREATED CHRONIC HEPATITIS B PATIENTS  doi:10.1136/gutjnl-2013-304907.432 1,2 R Ajayi, 1,*V K Snowdon, 1A Pellicoro, 1P Ramachandran, 2W Mungall, 3M Jansen, 3R Lennen, 1R Aucott, 1,*V Sagar, 2N N Than, 3S Naqvi, 3S Singhal. 1Medicine, Heart of UK NHS Foundation Trust; 2Gastroenterology, Medicine, University Hospitals Birmingham NHS Foundation Trust; 3Gastroenterology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK

Introduction  Tenofovir Disoproxil Fumarate (TDF) is an established oral antiviral (OAV) in the treatment of Chronic Hepatitis B (CHB). Bone Mineral Density (BMD) loss has been described in TDF treated HIV patients, but limited data exist in CHB. We have used DEXA scanning to determine BMD changes in TDF treated patients and have reported the possibility of BMD loss. DEXA scanning, however, is costly and requires longitudinal follow-up. We assessed the value of the FRAX® score and of bone biochemistry to evaluate their utility in TDF treated patients.

Methods  The FRAX score is a WHO web-based tool, used to calculate 10-year fracture risk and the need for lifestyle modification, DEXA scanning or preventative treatment. CHB patients treated with TDF for a minimum of 12-months and a control group not exposed to TDF were studied. 122 TDF exposed patients (male = 69), median age 45 (range = 26–64) and 48 patients (male = 31), median age 36 (range = 20–62) not exposed to TDF were DEXA scanned and included in the study. We calculated FRAX scores and recorded bone biochemical markers, comprising serum Alkaline Phosphatase (sALP), Calcium (sCa) and Phosphate (sP).

Results  TDF treated patients had lower hip T-scores compared to controls (p = 0.02). On univariate analysis factors associated with a hip T-score < 1 included older age, lower BMI, smoking and TDF exposure (p < 0.05). On multivariate analysis the same factors were associated with a hip T-score < 1, but TDF lost significance. For the development of a major osteoporotic fracture the pre-DEXA FRAX score was 4.77% compared to 4.33% (post-DEXA FRAX) (p = 0.9) and for a hip fracture this was 0.54% (pre-DEXA FRAX) and 0.77% (post-DEXA FRAX) (p = 0.5). The pre-DEXA FRAX score was a significant predictor of the post-DEXA FRAX treatment recommendation (p = < 0.001). TDF therapy was associated with increased sALP after 12-months, but this was not significant. No change was observed in pre-treatment sCa and sPO levels compared to those after 12-months exposure (p = 0.5 & 0.09 respectively).

Conclusion  Our results demonstrate the FRAX score alone can accurately predict the risk of developing an osteoporotic fracture in TDF treated CHB patients. This potentially obviates the need for DEXA scanning and the associated costs. The relationship between sALP and TDF is noteworthy, but bone parameters are of limited use in predicting BMD changes. Although BMD loss in TDF treated CHB patients remains unproven, we demonstrate the use of the FRAX score may determine those at risk of osteoporotic fractures in CHB.

Disclosure of Interest  None Declared.

PWE-145  RESTROSPECTIVE REVIEW OF HEPATITIS B DATABASE  doi:10.1136/gutjnl-2013-304907.433 1R Aucott, 1,*V Sagar, 2N N Than, 3S Naqvi, 3S Singhal. 1Medicine, Heart of UK NHS Foundation Trust; 2Gastroenterology, Medicine, University Hospitals Birmingham NHS Foundation Trust; 3Gastroenterology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK

Introduction  Chronic Hepatitis B Virus (HBV) affects 350 million people worldwide with potential serious consequences. The aim of this study was to measure adherence at Sandwell and West Birmingham Hospitals (SWBH) NHS Trust to recent guidance regarding HBV assessment and treatment.

Methods  A retrospective review of the SWBH HBV database (2008–2012) was undertaken. On the basis of European Association for the Study of the Liver (EASL) guidance, attainment of the following outcomes (standard 100%) was calculated: ALT measurement, liver ultrasound (US) examination, HBV DNA measurement, HIV testing, further liver assessment where indicated (using biopsy or Fibroscan) and use of antiviral therapy where indicated.

Results  322 patients with HBV were identified. Attainment of the EASL standards were as follows: ALT measurement 92%, liver US examination 80%, HBV DNA measurement 95%, HIV testing 72%, further liver assessment where indicated 82% and use of antiviral therapy where indicated 100%.

Conclusion  In general patients were managed according to EASL guidelines. Liver US examination was not 100% mainly because patients failed to attend their appointment. HIV testing was not 100% as routine testing in HBV patients was introduced only in 2008. Further liver assessment with biopsy was deferred in a number of cases after discussion between patient and physician; recent acquisition of a Fibroscan at SWBH should increase the proportion of appropriate patients undergoing further liver assessment. It is encouraging that all patients received antiviral therapy where indicated. It is hoped that data from this review and recent acquisition of a Fibroscan at SWBH Trust will promote improved adherence to guidelines.

Disclosure of Interest  None Declared.

REFERENCES
1. AASLD practise guidelines 2009: Chronic Hepatitis B

PWE-146  RELAXIN IS A RENAL VASODILATOR IN EXPERIMENTAL MODELS OF CIRRHOSIS AND A POTENTIAL NOVEL THERAPY FOR HEPATORENAL SYNDROME IN HUMANS  doi:10.1136/gutjnl-2013-304907.434 1V K Snowdon, 1*A Pellicoro, 1P Ramachandran, 2W Mungall, 3M Jansen, 3R Lennen, 1R Aucott, 1*T Kendall, 1J Hughes, 1J Priede, 1J A Fallowfield. 1*MRC/Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh; 2*Biomedical Research Resources, University of Edinburgh; 3*Edinburgh Preclinical Imaging, BHF/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

Introduction  Hepatorenal syndrome (HRS) is a feared complication of cirrhosis with a high mortality rate and limited treatment options. The hallmark features of HRS are profound renal vasconstriction, resulting in a functional renal failure but with normal kidney histology. The peptide hormone relaxin (RLN) mediates maternal haemodynamic adaptations to pregnancy, including increased renal blood flow (RBF) and glomerular filtration rate (GFR). We hypothesised that RLN could beneficially modulate RBF in cirrhosis and HRS.

Methods  Cirrhosis, with reduced RBF was induced in rats by 16 weeks of intraperitoneal (i.p.) carbon tetrachloride (CCL) and decapitated embryonic cirrhosis by 3 weeks bile duct ligation (BDL). We measured the effect of acute intravenous (i.v.) and extended (72 hr) subcutaneous (s.c.) RLN on systemic haemodynamics, RBF, GFR and organ histology. Subgroups of rats were co-treated with the nitric oxide (NO) synthase inhibitor L-NAME. Blood oxygen